RxDoctor Payments DataLook up a doctor →

Russell Perry, MD

Allergy & Immunology · Beaumont, TXNPI 1780770362

Payments from drug & device makers

$3,201,402in general payments, 2019–2025

Across 781 payments — averaging $4099.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.8M
  • AbbVie$210K
  • Modernatx, Inc.$132K
  • Genentech USA, Inc.$30K
  • Galderma Laboratories, L.p.$8K
  • AstraZeneca$3K
  • plus $13K from 37 others
$48,970in research payments, 2019–2025

Across 7 payments — averaging $6995.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$49K

What the payments were for

  • Consulting fees$2,1355%
  • Speaking & faculty fees$24,99055%
  • Travel & lodging$2,4035%
  • Food & beverage$15,52034%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,201,402 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$260,719
Medicare patients
60
Services billed
9,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo12$305,797
Dupixent SyringeDupilumab11$62,410
XolairOmalizumab17$56,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$45,214
Breo ElliptaFluticasone/Vilanterol15$7,595
Azelastine-FluticasoneAzelastine/Fluticasone17$4,033
Epinephrine12$2,770
Wixela InhubFluticasone Propion/Salmeterol15$1,157
Montelukast Sodium71$671
Albuterol Sulfate HfaAlbuterol Sulfate14$338
Prednisone58$224
Fluticasone Propionate11$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$442$305,79712 claims
Genentech, Inc.Xolair$85$56,12417 claims
GSKTrelegy Ellipta, Breo Ellipta$1,432$52,81063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →